博腾股份(300363) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥542,859,651.10, representing a 38.99% increase compared to ¥390,571,812.66 in the same period last year[6] - Net profit attributable to shareholders was ¥88,091,336.52, an increase of 82.90% from ¥48,164,934.36 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥75,267,992.56, up 55.72% from ¥48,336,440.22 in the previous year[6] - The basic earnings per share increased to ¥0.16, a rise of 77.78% compared to ¥0.09 in the same period last year[6] - The overall gross margin improved to 40.39%, an increase of 2.45 percentage points compared to the same period last year, while the net margin rose to 16.15%, up 4.09 percentage points[25] - Net profit for Q1 2021 reached CNY 87,676,028.93, a significant increase of 86% compared to CNY 47,115,764.27 in the same period last year[72] - The company reported a basic and diluted earnings per share of CNY 0.16, compared to CNY 0.09 in Q1 2020[72] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,683,978,701.75, a 4.16% increase from ¥4,496,939,175.86 at the end of the previous year[6] - The net assets attributable to shareholders increased to ¥3,473,426,009.80, reflecting a 2.42% growth from ¥3,391,430,127.18 at the end of the previous year[6] - Total liabilities amounted to CNY 1,208,922,197.61, compared to CNY 1,103,697,701.72, reflecting an increase of 9.5%[63] - The total current liabilities increased to CNY 1,028,198,822.30 from CNY 984,022,123.94, an increase of 4.5%[63] Cash Flow - The net cash flow from operating activities was ¥35,593,516.02, a decrease of 64.62% compared to ¥100,608,444.60 in the same period last year[6] - The cash flow from operating activities showed improvement, with a net cash inflow of CNY 50,000,000 compared to a net outflow in the previous year[20] - The total cash and cash equivalents at the end of the period decreased to ¥990,206,419.62 from ¥1,165,567,157.85 year-over-year[78] - Cash paid to employees increased to ¥137,993,113.18, compared to ¥96,429,073.41 in the same quarter last year, reflecting a 43.3% increase[77] Investments and R&D - Research and development expenses surged by 98.07% to CNY 65,675,223.56, indicating a strong commitment to innovation and product development[20] - The company expanded its gene and cell therapy CDMO business, serving 7 clients and establishing a GMP production platform for various products[35] - The company has continued to advance its formulation CDMO business, achieving collaboration with 9 clients during the reporting period[38] - The company completed a financing round in April 2021, raising CNY 400 million to enhance its gene therapy business capabilities[35] Market and Business Strategy - The company plans to expand its market presence and enhance its product offerings through strategic partnerships and acquisitions in the coming quarters[20] - The company is focusing on transitioning from CMO to CDMO business models to optimize project investment[54] - Major risks include potential market demand fluctuations for innovative drugs, which could significantly affect sales and overall performance[40] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,137[9] - Shareholders with over 5% stakes have pledged significant shares, with the largest pledges being 45.47 million shares, representing 8.38% of total shares[44] - The company plans to reduce shares by up to 5,404,473 shares, representing 1% of the total share capital of 540,747,533 shares, starting from December 1, 2020[46] Other Notable Events - The company has initiated a new leasing standard, resulting in the recognition of lease liabilities amounting to CNY 124,091,256.10[19] - The company has liquidated and deregistered its subsidiary, Chongqing Dexin Pharmaceutical Technology Partnership, due to unmet fundraising expectations influenced by external macroeconomic conditions and the COVID-19 pandemic[46] - The company approved the 2021 Restricted Stock Incentive Plan, which aims to enhance sustainable development and protect shareholder interests[47]